ipollit : Medigene kauft Munich Biotech!
3 Medikamente in PhaseI/II, wovon eines ein Potential von "über 500 Mio USD" besitzen soll, eine komplette Technologieplattform, Mitarbeiter und 4 Mio Cash... für eine 15% KE. Die MK ist dann bei ca. 90 Mio EUR.
Bin mal gespannt, wie die Börse am Montag darauf reagiert. (Kam ja erst nach Börsenschluß und die meisten scheinen schon zu pennen oder Party zu machen ;-) )
Our "anti-neovascular cytotoxics?, a new class of innovative cancer drugs exhibit an unique mode of action. By destroying newly formed, angiogenic blood vessels of solid tumors these agents are potentially effective in "chocking? of both the primary tumor and metastases, reducing tumor volume and inducing remission in all solid tumors. Our products thereby address unmet medical needs with high medical and economic impact. We strive to provide a safe and effective treatment, keeping up the quality of life of our patients.
Our unique products offers a number of advantages over conventional chemotherapy. In contrast to other approaches in the highly segmented market of anti-cancer therapies, our anti-neovascular cytotoxics have broad potential in a wide variety of solid tumors and metastases. With this universal approach, we address a global multibillion-dollar market in oncology. Our technology also looks very promising in other disease areas like wound healing or inflammation, where neo-vascularization can occur. Munich Biotech collaborates with strategic partners who will support various aspects of its research, preclinical programs and clinical development, manufacturing and marketing of these products.
mfg ipollit :-)